Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt No Debt
CRMD's Cash to Debt is ranked higher than
81% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: 61.14 vs. CRMD: No Debt )
Ranked among companies with meaningful Cash to Debt only.
CRMD' s Cash to Debt Range Over the Past 10 Years
Min: 0.11  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.92
CRMD's Equity to Asset is ranked higher than
89% of the 703 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. CRMD: 0.92 )
Ranked among companies with meaningful Equity to Asset only.
CRMD' s Equity to Asset Range Over the Past 10 Years
Min: -1.36  Med: 0.71 Max: 0.92
Current: 0.92
-1.36
0.92
F-Score: 5
Z-Score: 23.98
M-Score: 0.11
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -7930.95
CRMD's Operating margin (%) is ranked lower than
93% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -65.33 vs. CRMD: -7930.95 )
Ranked among companies with meaningful Operating margin (%) only.
CRMD' s Operating margin (%) Range Over the Past 10 Years
Min: -245750  Med: -7930.48 Max: -4710.05
Current: -7930.95
-245750
-4710.05
Net-margin (%) -8660.48
CRMD's Net-margin (%) is ranked lower than
93% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -63.93 vs. CRMD: -8660.48 )
Ranked among companies with meaningful Net-margin (%) only.
CRMD' s Net-margin (%) Range Over the Past 10 Years
Min: -456650  Med: -10821.69 Max: -8660.95
Current: -8660.48
-456650
-8660.95
ROE (%) -76.89
CRMD's ROE (%) is ranked lower than
75% of the 856 Companies
in the Global Biotechnology industry.

( Industry Median: -30.96 vs. CRMD: -76.89 )
Ranked among companies with meaningful ROE (%) only.
CRMD' s ROE (%) Range Over the Past 10 Years
Min: -687.26  Med: -156.31 Max: -96.8
Current: -76.89
-687.26
-96.8
ROA (%) -69.92
CRMD's ROA (%) is ranked lower than
81% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: -26.04 vs. CRMD: -69.92 )
Ranked among companies with meaningful ROA (%) only.
CRMD' s ROA (%) Range Over the Past 10 Years
Min: -507.14  Med: -190.85 Max: -86.2
Current: -69.92
-507.14
-86.2
ROC (Joel Greenblatt) (%) -42877.36
CRMD's ROC (Joel Greenblatt) (%) is ranked lower than
96% of the 899 Companies
in the Global Biotechnology industry.

( Industry Median: -363.62 vs. CRMD: -42877.36 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CRMD' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -53119.48  Med: -39944.84 Max: -35182.61
Current: -42877.36
-53119.48
-35182.61
EBITDA Growth (3Y)(%) 29.70
CRMD's EBITDA Growth (3Y)(%) is ranked higher than
83% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: -0.80 vs. CRMD: 29.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CRMD' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -66.5  Med: 0.70 Max: 29.7
Current: 29.7
-66.5
29.7
EPS Growth (3Y)(%) 25.20
CRMD's EPS Growth (3Y)(%) is ranked higher than
79% of the 488 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. CRMD: 25.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CRMD' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -68.5  Med: 1.10 Max: 25.2
Current: 25.2
-68.5
25.2
» CRMD's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-05-08)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

CRMD Guru Trades in Q1 2015

Jim Simons 47,600 sh (New)
Paul Singer 1,500,200 sh (+91.98%)
» More
Q2 2015

CRMD Guru Trades in Q2 2015

Paul Singer 1,500,200 sh (unchged)
Jim Simons Sold Out
» More
Q3 2015

CRMD Guru Trades in Q3 2015

Paul Singer 1,500,200 sh (unchged)
» More
Q4 2015

CRMD Guru Trades in Q4 2015

Paul Singer 1,500,200 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with CRMD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.50
CRMD's P/B is ranked lower than
61% of the 842 Companies
in the Global Biotechnology industry.

( Industry Median: 3.38 vs. CRMD: 3.50 )
Ranked among companies with meaningful P/B only.
CRMD' s P/B Range Over the Past 10 Years
Min: 1.3  Med: 4.33 Max: 31.85
Current: 3.5
1.3
31.85
P/S 469.97
CRMD's P/S is ranked lower than
94% of the 671 Companies
in the Global Biotechnology industry.

( Industry Median: 10.84 vs. CRMD: 469.97 )
Ranked among companies with meaningful P/S only.
CRMD' s P/S Range Over the Past 10 Years
Min: 151.11  Med: 364.00 Max: 2810
Current: 469.97
151.11
2810
EV-to-EBIT -4.58
CRMD's EV-to-EBIT is ranked lower than
99.99% of the 256 Companies
in the Global Biotechnology industry.

( Industry Median: 24.28 vs. CRMD: -4.58 )
Ranked among companies with meaningful EV-to-EBIT only.
CRMD' s EV-to-EBIT Range Over the Past 10 Years
Min: -22.6  Med: -2.30 Max: -0.2
Current: -4.58
-22.6
-0.2
EV-to-EBITDA -4.59
CRMD's EV-to-EBITDA is ranked lower than
99.99% of the 276 Companies
in the Global Biotechnology industry.

( Industry Median: 20.97 vs. CRMD: -4.59 )
Ranked among companies with meaningful EV-to-EBITDA only.
CRMD' s EV-to-EBITDA Range Over the Past 10 Years
Min: -22.6  Med: -2.30 Max: -0.2
Current: -4.59
-22.6
-0.2
Current Ratio 12.11
CRMD's Current Ratio is ranked higher than
81% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. CRMD: 12.11 )
Ranked among companies with meaningful Current Ratio only.
CRMD' s Current Ratio Range Over the Past 10 Years
Min: 0.1  Med: 2.09 Max: 12.11
Current: 12.11
0.1
12.11
Quick Ratio 11.98
CRMD's Quick Ratio is ranked higher than
81% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.54 vs. CRMD: 11.98 )
Ranked among companies with meaningful Quick Ratio only.
CRMD' s Quick Ratio Range Over the Past 10 Years
Min: 0.1  Med: 2.09 Max: 11.98
Current: 11.98
0.1
11.98
Days Inventory 623.25
CRMD's Days Inventory is ranked lower than
97% of the 441 Companies
in the Global Biotechnology industry.

( Industry Median: 121.91 vs. CRMD: 623.25 )
Ranked among companies with meaningful Days Inventory only.
CRMD' s Days Inventory Range Over the Past 10 Years
Min: 72.28  Med: 222.19 Max: 480.56
Current: 623.25
72.28
480.56
Days Sales Outstanding 549.24
CRMD's Days Sales Outstanding is ranked lower than
97% of the 602 Companies
in the Global Biotechnology industry.

( Industry Median: 65.97 vs. CRMD: 549.24 )
Ranked among companies with meaningful Days Sales Outstanding only.
CRMD' s Days Sales Outstanding Range Over the Past 10 Years
Min: 154.5  Med: 365.00 Max: 549.24
Current: 549.24
154.5
549.24
Days Payable 1.00
CRMD's Days Payable is ranked lower than
97% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: 64.47 vs. CRMD: 1.00 )
Ranked among companies with meaningful Days Payable only.
CRMD' s Days Payable Range Over the Past 10 Years
Min: 730.82  Med: 1698.51 Max: 1955.44
Current: 1
730.82
1955.44

Valuation & Return

vs
industry
vs
history
Price/Net Cash 3.66
CRMD's Price/Net Cash is ranked higher than
56% of the 495 Companies
in the Global Biotechnology industry.

( Industry Median: 5.42 vs. CRMD: 3.66 )
Ranked among companies with meaningful Price/Net Cash only.
CRMD' s Price/Net Cash Range Over the Past 10 Years
Min: 2.26  Med: 3.54 Max: 14.69
Current: 3.66
2.26
14.69
Price/Net Current Asset Value 3.50
CRMD's Price/Net Current Asset Value is ranked higher than
56% of the 613 Companies
in the Global Biotechnology industry.

( Industry Median: 5.24 vs. CRMD: 3.50 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CRMD' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.16  Med: 2.72 Max: 11.94
Current: 3.5
2.16
11.94
Price/Tangible Book 3.46
CRMD's Price/Tangible Book is ranked lower than
52% of the 776 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. CRMD: 3.46 )
Ranked among companies with meaningful Price/Tangible Book only.
CRMD' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.15  Med: 2.63 Max: 11.79
Current: 3.46
2.15
11.79
Price/Projected FCF 10.28
CRMD's Price/Projected FCF is ranked lower than
78% of the 176 Companies
in the Global Biotechnology industry.

( Industry Median: 3.66 vs. CRMD: 10.28 )
Ranked among companies with meaningful Price/Projected FCF only.
CRMD' s Price/Projected FCF Range Over the Past 10 Years
Min: 6.34  Med: 27.05 Max: 47.75
Current: 10.28
6.34
47.75
Price/Median PS Value 1.29
CRMD's Price/Median PS Value is ranked lower than
77% of the 574 Companies
in the Global Biotechnology industry.

( Industry Median: 0.95 vs. CRMD: 1.29 )
Ranked among companies with meaningful Price/Median PS Value only.
CRMD' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.58  Med: 0.69 Max: 0.8
Current: 1.29
0.58
0.8
Earnings Yield (Greenblatt) (%) -21.82
CRMD's Earnings Yield (Greenblatt) (%) is ranked lower than
65% of the 897 Companies
in the Global Biotechnology industry.

( Industry Median: -7.90 vs. CRMD: -21.82 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CRMD' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -1325.05  Med: 0.00 Max: 0
Current: -21.82
-1325.05
0

More Statistics

Revenue(Mil) $0
EPS $ -0.61
Beta-0.25
Short Percentage of Float15.13%
52-Week Range $1.15 - 7.96
Shares Outstanding(Mil)36.12

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 1 2 4
EPS($) -0.49 -0.50 -0.35
EPS without NRI($) -0.49 -0.50 -0.35

Business Description

Industry: Biotechnology » Biotechnology
Compare:AMEX:AMPE, LSE:TRX, NAS:CYTR, AMEX:NAVB, XKRX:041910, NAS:PETX » details
Cormedix Inc was organized as a Delaware corporation on July 28, 2006 under the name Picton Holding Company, Inc. and changed it to CorMedix Inc. on January 18, 2007. The Company develops and seeks to commercialize products for the treatment of cardiac, renal and infectious diseases. Its principal product under development includes CRMD003, an antimicrobial/anticoagulant solution applied in the prevention of catheter related bloodstream infections and maintenance of catheter patency in central venous catheters used for vascular access in hemodialysis patients. Its products also include CRMD004, a pressure sensitive gel that is in pre-clinical Phase.
» More Articles for CRMD

Headlines

Articles On GuruFocus.com
Paul Singer's Latest Portfolio Increases and Reduction Mar 04 2015 
Weekly CFO Buys Highlight: CEP, JNS, CRMD, VAC, TICC Dec 26 2011 
Weekly CFO Buys Highlight: POL, ARAY, ZBB, CRMD, VRX Dec 19 2011 
CORMEDIX INC Reports Operating Results (10-Q) Nov 09 2010 

More From Other Websites
CorMedix Announces Publication of Neutrolin(R) Data to be Presented at the 1st Gulf Congress of... May 05 2016
SPO Advisory Trims Stake in Embattled Resolute Energy Corp (REN), Plus Three Other Hedge Fund Moves May 03 2016
ETF’s with exposure to CorMedix, Inc. : May 2, 2016 May 02 2016
CORMEDIX INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements... May 02 2016
CorMedix Appoints Myron Kaplan to Board of Directors May 02 2016
CORMEDIX INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year Apr 25 2016
CORMEDIX INC. Files SEC form 8-K, Change in Directors or Principal Officers Apr 21 2016
CorMedix to Present Data from Landmark Post-Approval Surveillance Study at National Kidney... Apr 21 2016
CorMedix to Present at the 1st Gulf Congress of Clinical Microbiology and Infectious Diseases Apr 19 2016
CORMEDIX INC. Files SEC form 8-K, Other Events Apr 13 2016
CorMedix Inc. to Present Post-Market Clinical Utility Data from Neutrolin® Usage Monitoring Program... Apr 12 2016
Is CorMedix an Incredible Momentum Stock? 3 Reasons Why CRMD Will Be Tough to Beat Apr 12 2016
CorMedix Inc. to Present Post-Market Clinical Utility Data from Neutrolin(R) Usage Monitoring... Apr 12 2016
CorMedix Proprietary Antimicrobial Technology Featured at the ASAPS Aesthetic Meeting 2016 Apr 08 2016
CorMedix Inc. to be Featured on Panel at FBR & Co. Healthcare Series Event Focused on Infectious... Apr 06 2016
ETF’s with exposure to CorMedix, Inc. : April 4, 2016 Apr 04 2016
CorMedix Inc. to Present New Pharmacoeconomic Data Demonstrating Cost of Catheter-Related Infections... Mar 23 2016
CorMedix, Inc. :CRMD-US: Earnings Analysis: Q4, 2015 By the Numbers Mar 21 2016
CORMEDIX INC. Financials Mar 19 2016
CORMEDIX INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Mar 16 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK